Spero Therapeutics (SPRO) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order at 9:00 A.M. as a live webcast to maximize stockholder participation.

• Board members and key executives were introduced, along with external advisors from PricewaterhouseCoopers and WilmerHale.

• The agenda included five proposals: election of directors, ratification of auditors, advisory vote on executive compensation, amendment to increase authorized shares, and approval of a new stock incentive plan.

Shareholder proposals

• Proposals included electing two Class III directors for three-year terms, ratifying the independent auditor, approving executive compensation, amending the certificate of incorporation to double authorized shares, and adopting a new stock incentive plan.

Overview of voting outcomes

• A quorum was established with proxies for 70.9% of outstanding shares.

• Both director nominees were elected for three-year terms.

• Ratification of PricewaterhouseCoopers as auditor was approved.

• Advisory approval of executive compensation passed.

• Amendment to increase authorized shares from 120 million to 240 million was approved.

• The 2026 stock incentive plan was approved to replace the expiring 2017 plan.

• Full voting results will be published in a forthcoming SEC Form 8-K.